Abstract
Preliminary Safety Profile of the CD19-Directed Defined Composition CAR T Cell Product JCAR017 in Relapsed/Refractory Aggressive B-NHL Patients: Potential for Outpatient Administration
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have